Study #COGAALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precurson Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC#606869) in the Very High Risk Stratum
MD Anderson Study Status
Not Accepting
Treatment Agent
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate, Daunorubicin Hydrochloride, Hydrocortisone Sodium Succinate, Etoposide, Clofarabine, Dasatinib
Description
This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Study phase:
Phase III
Physician name:
Najat Daw Bitar
Department:
Pediatrics
For general questions about clinical trials:
1-855-583-2881
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.